tiprankstipranks
Trending News
More News >
PolyPid Ltd. (PYPD)
NASDAQ:PYPD
US Market
Advertisement

PolyPid (PYPD) Drug Pipeline

Compare
388 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Standard Of Care (Soc), D-Plex
Surgical Site Infection, Colon Surgery, Abdominal Surgery, Post-Op Infection
Phase III
Completed
D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)
May 27, 2020
Standard Of Care (Soc), D-Plex
Surgical Site Infection, Colon Surgery, Abdominal Surgery, Post-Op Infection
Phase III
Completed
D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection
Jan 06, 2020

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does PolyPid Ltd. (PYPD) have in its pipeline
      PYPD is currently developing the following drugs: Standard Of Care (Soc), D-Plex, Standard Of Care (Soc), D-Plex. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis